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Abstract
Colorectal cancer is a significant source of morbidity and mortality in the United States and other
Western countries. Oral delivery of therapeutics remains the most patient accepted form of
medication. The development of an oral delivery formulation for local delivery of
chemotherapeutics in the gastrointestinal tract can potentially alleviate the adverse side effects
including systemic cytotoxicity, as well as focus therapy to the lesions. Here we develop an oral
formulation of the chemotherapeutic drug oxaliplatin for the treatment of colorectal cancer.
Oxaliplatin was encapsulated in pH sensitive, mucoadhesive chitosan-coated alginate
microspheres. The microparticles were formulated to release the chemotherapeutics after passing
through the acidic gastric environment thus targeting the intestinal tract. In vivo, these particles
substantially reduced the tumor burden in an orthotopic mouse model of colorectal cancer, and
reduced mortality.
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1. Introduction
Despite considerable efforts to improve early diagnosis and treatment, colorectal cancer
remains the third most common cancer in the world [1]. Platinum-based compounds such as
cis-diamminedichloroplatinum( II) (CDDP), carboplatin (CBDCA) and oxaliplatin (LOHP)
are important anticancer drugs [2]. Unfortunately, their therapeutic utility is limited by drug
resistance in tumors [3] and systemic toxicity [4,5]. In colorectal cancer therapy, as it is in
other cancers, biodistribution to tumor tissue can be limited and not reach effective
concentrations [6,7].
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Oral administration of drugs is the one of the most convenient and patient accepted methods
of drug delivery. However, the gastrointestinal microenvironment presents many delivery
challenges including the acidic conditions of the stomach, the proteolytic activity of the
gastrointestinal tract due to the presence of digestive enzymes, and the high density of
bacterial species. While intravenous (i.v.) administration of chemotherapeutics is common
practice, the oral route provides an anatomical advantage for delivering such agents, as it
permits direct access to the luminal tissue affected by many diseases.
One promising method for oral drug delivery involves the use of mucoadhesive biomaterials
such as chitosan and alginate. Chitosan’s mucoadhesion has been used in various clinical
applications including nasal administration of drugs [8], wound healing [9], as well as
transmucosal insulin delivery [10]. Similarly, alginates have been used as substrates for
vaginal delivery of siRNA [11], in particulate formulations for controlled gastric drug
release [12] or as patches for post-surgical tissue adhesion barriers [13].
Alginates are composed of α-L-guluronic acid (GG) and β-D-mannuronic acid (MM)residues
at varying proportions of GG-, MM-, and GM-blocks [14]. They are drug excipients, and
have been used as a matrix for cells in the field of tissue engineering. Alginic acid and its
salts are considered to be Generally Recognized as Safe (GRAS) according to the Food
Additive Status List [15] and have been used in the food industry as thickening agent,
preservative, antioxidant, flavoring agents, as well as an encapsulant material [16]. The
biological activity of drugs encapsulated in particles formulated with such materials can be
retained through the calcium-cross-linked alginate encapsulation process [17] and alginate is
non-toxic and biodegradable when given orally [18,19]. Moreover, alginates can be prepared
in a neutral or charged form, making them compatible with a variety of other materials, and
altering their material properties [20–22]. Chitosan is another polymer which demonstrated
utility in humans, and is biodegradable, mucoadhesive and relatively non-toxic in certain
applications [23].
Here we report an oral formulation for delivery of oxaliplatin to colorectal cancer tissue.
Such a formulation can be a significant alternative to the standard chemotherapeutic drug
delivery strategies. It can reduce the systemic level cytotoxicity; it can provide a patient
friendly method of drug administration as well as provide direct access to the GI tract tissues
of interest.
Thus the formulation developed here may have potential therapeutic applications for a
variety of diseases including colorectal cancer, as well as other GI related disorders such as
Irritable Bowel Syndrome (IBS), Crohn’s disease, and Colitis.
2. Methods
2.1. Preparation of the formulations
2.1.1. Formulation containing oxaliplatin—Oxaliplatin (Biotang Inc., Waltham, MA)
was dissolved in PBS using sonication, formulated with lipidoid nanoparticles and blended
with sterile 2% alginate solution. The mixture was loaded into a syringe and mounted onto a
pump. The entire procedure was performed under sterile conditions. Alginate microcapsules
were prepared aseptically using Harvard Apparatus PicoPlus Elite pump attached to a
voltage source. Microcapsules were collected into 0.1 M CaCl2 bath and left for 30 min
before washing twice with PBS. A solution of 0.5% chitosan was prepared by dissolving it
in 0.1% solution of acetic acid and at pH 5.2. The final dissolved mixture was sterile filtered
with 0.22 um. Parameters for microencapsulation were as follows: hardening time in CaCl2
– 30 min, coating time with 0.5% chitosan – 30 min, needle gauge – 18g, rate – 200 ul/min,
voltage - 10 kV and current 2 amp. Microencapsulation yielded homogenous spheres of 80 ±
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28 mm in diameter. Prepared microparticles were washed with sterile PBS and stored at 4
°C until used.
2.1.2. Formulation containing lipidoid nanoparticles—The C12-200 lipidoid
nanoparticles were formulated from lipidoid, cholesterol, and a polyethylene glycol
modified lipid as previously described [25]. Stock solutions of lipidoid, cholesterol (Sigma-
Aldrich), and a PEG lipid (N-palmitoyl-sphingosine-1-[succinyl[methoxy(polyethylene
glycol)2000]], MW 2634, Avanti Polar Lipids) were prepared in absolute ethanol at
concentrations of 100, 15, and 100 mg/mL, respectively. The components were then
combined and vortexed to yield weight fractions of 52:20:28. The ethanol mixture was then
added drop wise to 200 mM sodium acetate buffer (pH 5) in a glass vial with concurrent
stirring to spontaneously form empty lipidoid nanoparticles. After the particle formulation
they were incubated at room temperature for 30 min. The formulations were then dialyzed
against PBS in a 10 kDaMWCO dialysis cassette (Pierce, Rockford, IL) for 2 h. Following
buffer exchange, oxaliplatin solution in PBS at a concentration of 55 mg/kg was added to a
sample, each formulation was used for particle characterization; the drug entrapment was
estimated using UV spectroscopy and the mean particle size was quantified by dynamic light
scattering (ZetaPALS, Brookhaven Instruments).
2.2. Animals
All procedures used in animal studies were approved by the Institutional Animal Care and
Use Committee and were consistent with local, state and federal regulations as applicable.
Male C57BL/6J-ApcMin/+ mice, weighing w23 g, were purchased from the Jackson
Laboratory (Bar Harbor, ME, USA). The animals were kept in the Koch Institute Animal
Facility on a 12 h light–dark cycle and controlled humidity and temperature. They were
allowed sterile water and the laboratory rodent diet from Harlan ad libitum. Animals overall
health was monitored daily. The protocol was approved by the Animal Care Committee of
MIT and animals were cared for in accord with the Comparative Animal Care (CAC)
guidelines.
2.3. Animal protocol
Male C57BL/6J-ApcMin/+ mice were used. They were separated into two experimental
groups: Control - animals gavaged with empty alginate-chitosan (AC) microcapsules
suspended in PBS, Treatment group – animals gavaged with AC microencapsulated lipidoid
and oxaliplatin nanoparticles suspended in PBS. Upon arrival, animals were randomly block
assigned and allowed one week of acclimatization period. There were 10 animals per group.
Animals were weighed individually every week; the bleed from saphenous veinwas
performed every 3 weeks and fecal samples were collected weekly throughout the
experiment. If any animal during experiment had a body weight decrease of over 20%
within a week they were scheduled for euthanasia. Mice were CO2 euthanized at the end of
the experiment. Cardiac blood was collected and the entire small intestine, cecum and colon
were removed. Spleens were removed, weighted and measured. The rest of the organ was
made into a ‘Swiss-roll’, placed in a separate histology cassette and preserved in 4% neutral
buffered formalin solution.
2.4. Intestinal histopathology
After excising small intestine, cecum and colon, tissues were fixed with formaldehyde. A
formaldehyde solution (final concentration, 10% [wt/vol] paraformaldehyde) in phosphate-
buffered saline (130 mM sodium chloride, 10 mM sodium phosphate buffer, pH 7.2) was
used. The material was then incubated overnight in the refrigerator (4 °C) for fixation. After
fixation tissues were transferred to 70% ethanol. Sections with a thickness of 6 mmwere cut
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in the cryostat with a manual cryotome. Sections were directly picked up onto an adhesive,
electrostatically charged microscope slides (Fisherbrand Superfrost Plus Microscope Slides,
USA). This was done immediately after the microscope slides were introduced into the
cryostat. It was important that the microscope slides be at room temperature during this
procedure in order to allow adhesion and smoothing out of the thawing microtomic sections.
Subsequently, the mounted tissue holder was incubated at −22 °C for 1 h (precooling) in the
cryostat. Adenomas were visualized by staining tissue with hematoxylin and eosin stains.
They were identified, counted and measured with the aid of transmitted light microscope
Evos xl AMG, with imaging software. To assess mucin production, slides were treated with
Alcian Blue (pH2.5) for 5 min, then mounted using standard techniques. Slides were then
stored at −80 °C prior to immunostaining.
2.5. Immunohistochemistry
For immunohistochemistry staining sections were deparafinized in a series of xylene and
ethanol solutions (100%, 90%, 80% and 70%) followed by a hydration with distilled water.
Immunostaining was performed by the avidin-biotin complex technique using the Millipore
IHC SelectRTM HRP/DAB kit. Briefly, tissues were pretreated using a citrate buffer, pH 6.0
and blocked with normal serum from the kit for 10 min 3% hydrogen peroxidase treatment
was applied to samples for 2 min. Samples were rinsed with PBS buffer and incubated with
2% normal serum in PBS to avoid background staining. The slices were incubated with the
biotinylated secondary antibody for 10 min, rinsed and applied with Streptavidin-HRP
solution for 10 min. Negative control samples were produced by incubating the samples in
TBS plus 1% BSA without either of the biotinylated primary antibodies.
Nitrotyrosine antibody (Cayman, Ann Arbor, ME) was used at a dilution of 1:200. To access
mucin production, slides were treated with Alcian Blue pH 2.5 for 5 min, and then mounted
using standard techniques.
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay
was done with an in situ cell death detection kit (Roche, Branchburg, NJ). Briefly,
deparafinization of tissues was performed as described before. The slides were hydrated in
PBS buffer for 30 min. Subsequently, tissues were digested for 30 min with Proteinase K
(Roche, Branchburg, NJ). Slides were rinsed with PBS twice. Label solution was added to
enzyme solution and mixed to equilibrate components. Reaction mixture was added onto
each slide and the sections were incubated for 60 min in a humidified atmosphere chamber
in the dark. Lack of TdT in the TUNEL mix completely abolished labeling under all
working conditions and therefore served as TUNEL negative control. Tissue sections were
analyzed in a drop of PBS buffer under a fluorescence microscopy at an excitation
wavelength of 450 nm and detection range of 515–565 nm. Further, signal conversion was
performed using converter-POD; slides were incubated for 30 min at RT in a humidified
atmosphere chamber in the dark at RT. Slides were rinsed 3 times with PBS and 0.05%
3-3′-diaminobenzidine tetrahydrochloride (DAB) substrate was added onto each slide and
incubated for 10 min at RT. Next, slides were washed with PBS buffer 3 times and
counterstained with hemotoxylin and eosin for w60 s each. The samples were mounted in an
aqueous solution (VectaMount AQ, Vector Laboratories, Inc.) and covered with a coverslip
to analyze under fluorescent microscope Evos fl AMG, with imaging software.
All of the kits were used according to the manufacturers’ instructions.
2.6. Polyp counting
Polyp scoringwas performed by a person blinded to the experimental setup. The adenomas
observed were divided into two categories based on the size: gastrointestinal intraepithelial
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neoplasia (GIN)(<1 mm) and adenoma (>1 mm). In addition, the counted polyps were
graded as follows: (small intestines) no polyps: score 0; up to 5: score 1; up to 10: score 2;
from 11 to 15: score 3 and above 15: score 4; (large intestines) no polyps: score 0; up to 1:
score 1; up to 2: score 2; up to 3 score: 3; up to 4 score: 4 and above 5: score 5.
The standards for the histological assessment were established from the MMHCC-sponsored
symposium.
2.7. Fecal extraction; lactoferrin and C-reactive protein determination
Feces were collected weekly throughout the experiment and the analysis was averaged per
group per cage. Fecal extractionwas performed as previously described [26] with the
following modifications. 800 µL of sample were added to 400 µL of 3 M NaOH and heated
at 95 °C for 2hr. A mouse Lactoferrin Elisa (TSZ Elisa, Framingham, MA) was used to
determine the concentration of the protein and C-Reactive Protein concentration was
determined using a mouse Elisa kit from Life Diagnostics, Inc (West Chester, PA).
2.8. Statistical analysis
Data were analyzed using a one-way analysis of variance with Student Newman-Keuls post
hoc analysis. All data were analyzed using a commercial software SigmaStat; SPSS. Data
were expressed as means ± standard error of the mean. Data were considered significant at p
< 0.05.
3. Results
3.1. Survival, body weight and rectal bleeding
One characteristic of colorectal tumor progression is patient weight reduction and the
presence of blood in the stool [27,28]. Body weight decrease is attributed to chronic
constipation and abdominal pain whereas bleeding can be caused by the friction and shear of
the stool with the projecting interstitial tumors [29,30]. Given the significance of these
features to the disease progression, we monitored, on weekly basis, the animal body weight
and rectal bleeding.
In Fig. 1A we plot the progression of the body weight for the 17 weeks of treatment for two
animal groups, control group receiving empty AC microcapsules and treatment group
receiving microencapsulated lipidoid nanoparitcles containing oxaliplatin. All animals
gained weight steadily up to the 6th week. For the next two weeks, animals from the control
group lost weight however, with final body weight observed, 22.58 ± 1.2 g. Animals from
treatment group continued to gain weight and had terminal weights of 26.42 ± 1.6 g. During
daily health monitoring, we examined animal integument, erythema, haircoat condition,
status of hydration and pruritus. There were no severe cases observed apart from few
animals being dehydrated, all of which would receive subqutaneously injection of sterile
PBS. Based on daily observations of animal overall health, we noticed lack of coordination
along with slight body shivering and hunched in some animals of control group receiving
empty AC microcapsules suspended in saline. These animals also had a higher incidence of
rectal bleeding/blood in the stool when compared to the treatment group. They were
characterized by lack of energy and decreased motion rate. They acted restless with curled
bodies and lowered heads. No changes in muscular disturbances such as generalized
tremors, lip drooping and/or paralysis were noted in any animal.
3.2. Inflammation biomarkers and intestinal tumorigenesis
Many cancers are associated with chronic inflammation [31]. There are many chemokines
and cytokines involved in the recruitment and trafficking of inflammatory cells to the sites
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of tumor development [32]. The expression of various chemokines by intestinal cells,
particularly those of the epithelium, is a key to the development of an inflammatory
response. In such situation the macrophages detect tumor antigens and secrete IL-12, which
activates T cells and leads to the secretion of IFN-γ and TNF-α [33,34]. Those chemokines
in turn stimulate the tissue residing or recruited macrophages to produce proinflammatory
cytokines like IL-1β, TNF-α and IL-6. Such cytokines can in turn trigger the upregulation of
secondary inflammation markers like lactoferrin and C-reactive protein. Here we quantify
the expression of these inflammation markers and follow their levels along the progression
of the disease.
During the 17-week experimental period, collected blood serum was used to measure the
levels of inflammatory interleukin-6 and -12. The concentration levels were significantly
higher in control group compared to treatment group (Fig. 2A,B). For IL-12, at the time of
sacrifice the average levels were 47.55 ± 10.06 pg/mL for control and 20.71 ± 4.65 pg/mL,
and for treatment group. In addition, the levels of proinflammatory cytokine, IL-6 were
measured in serum. They were 28.23 ± 3.84 pg/mL for control and 17.21 ± 1.17 pg/mL for
treated animals at the time of sacrifice.
Lactoferrin was measured as a marker for fecal leukocytes. This test is more sensitive than
microscopy for identifying leukocytes and discriminates between inflammatory and non-
inflammatory bowel processes [35]. Lactoferrin concentration was determined from fecal
samples. The averages levels at the time of sacrifice were 33.11 ± 2.28 pg/mL for control
and 23.15 ± 1.29 pg/mL for treatment animals at the time of sacrifice, and; Fig. 3A.
Another marker for acute phase inflammation is C-reactive protein (CRP). CRP is
synthesized in the liver in response to cytokines like IL-6 and its increased levels can be
indicative of the inflammatory state [36,37]. C-reactive protein levels in the fecal samples
were determined by enzyme-linked immunosorbent assay, no significant changes were
observed within groups: 77.69 ± 4.13 ng/mL in control group, compared to 58.90 ± 6.28 ng/
mL in oxaliplatin group at the 17th week of treatment; Fig. 3B.
3.3. Morphological characteristics of tumors
We performed histopathology analysis, using H&E staining, of the different GI
compartments namely the small intestine, cecum and colon, of treated animals. Tumors were
scored and classified according to their size. As shown in Fig. 4, the tumors found in control
group animals were predominantly tubular adenomas with a pedunculated morphology
greatly protruding into the colonic lumen. However, there was no evidence of invasion of
the underlying submucosa by neoplastic epithelial cells, and therefore none of the adenomas
examined were classified as being carcinomas. Within control group there were high-grade
dysplasia adenomas with foci of intraluminal necrosis. A representative tumor of the small
intestine shows pedunculated (polypoid) adenoma with a high-grade of dysplasia (Fig. 4 –
top panel, indicated by arrows). A representative animal from oxaliplatin treatment group
depicts gastrointestinal intraepithelial neoplasia (microadenomas) of small intestine (Fig. 4-
bottom panel).
Furthermore we observed an increase in nuclear/cytoplasmic ratio and the nuclear crowding
at the lamina propria/crypt within oxaliplatin group in the small, colon and cecum. In both
groups, tumors in the small intestine were mostly less than 1 mm in diameter. The control
group animals had significantly higher polyp count, on average 15.2 in the small intestine,
0.33 in cecum and 1 in colon. In the oxaliplatin treatment group we counted 10.1 tumors in
the small intestine, 0.11 in cecum and 0.44 in colon; Table 1A. The number of tumors was
also scored according to a 0e5 scale (Materials and Methods), with 0 the no tumor condition
and 5 the most advanced disease state. The scores are presented in Table 1B. Finally,
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spleens’ weights and lengths were recorded, Table 1C. They were on average in control
group 2.33 ± 0.25 cm in length and 485 ± 8.21 mg in weight. In the oxaliplatin group they
were 2.28 ± 0.14 cm and 404 ± 10.08 mg.
3.4. Immunohistochemistry
Using terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL), an
in situ method for detecting the 3′-OH ends of DNA exposed during the internucleosomal
cleavage that occurs during apoptosis we evaluated the apoptotic state of tumor cells in the
small and large intestinal tissues. We expect an increased number of apoptotic cells in the
conditions that we deliver oxaliplatin. In the tumor of the untreated mice we found only few
fluorescently labeled cells, primarily located on the peripheral surface of the tumors, where
the oldest cells reside, Fig. 5A. When compared to the oxaliplatin treatment condition we
observed fluorescently labeled cells throughout the tumor, Fig. 5B.
Also, we investigated the mucin production by staining with alcian blue to detect mucous-
producing Goblet cells. Decreased mucin levels are correlated with a pathologic condition.
The greatest amounts of mucin producing cells were found in the normal intestinal tissues,
Fig. 5D whereas significantly reduced numbers were detected in the areas with tumors, Fig.
5C.
Nitrotyrosine levels in the small intestine of control and treatment group were evaluated in a
representative animal. Nitrotyrosine is a product of tyrosine nitration mediated by reactive
nitrogen species such as peroxynitrite anion and nitrogen dioxide. It is detected in large
number of pathological conditions and is considered a marker of nitric oxide dependent
nitrative stress. There was an increased level of nitrotyrosine in the microvilli of the small
intestine of untreated animal, Fig. 5E relative to the small intestine stained with cells
expressing nitric oxide only at the peaks of microvilli, Fig. 5F.
To further investigate the inflammatory changes, we analyzed intestinal tissues to see
whether there was an increase in the cycling/proliferating cells within the small and large
intestine, and to determine the potential treatment effect on recruitment of T cells as well as
cell proliferation and apoptosis, Fig. 6A (small intestine) and B (colon).We assessed the
inflammatory changes in the tumors of the control and oxaliplatin treatment animals found
in the intestine and colons by immunohistochemistry using of cyclooxygenase-2 (Cox-2),
cleaved caspase-3, Ki-67 and mdm-2 antibodies. Overall there was a greater concentration
of Cox-2 expressing cells in the control group versus treatment. Cleaved caspase-3
expressing cells, apoptotic cells, were mostly located in the tumors of oxaliplatin treatment
animals. The Ki-67 staining has not revealed significant differences between cell
populations between groups. Mdm-2 expressing cells were fewer, scarcely located within
tumors of treatment group animals.
4. Discussion
Platinum containing chemotherapeutics are a standard therapy for many patients [38–40].
However, to our knowledge, the utility of these drugs for colorectal cancer therapy
following oral administration has not been demonstrated. Here we developed an oral
formulation of oxaliplatin for colorectal cancer therapy. Our findings demonstrate that in
mice, oral formulations of oxaliplatin can be developed with potential utility against
colorectal cancer.
This study used an established mouse model of intestinal tumorigenesis with the multiple
intestinal neoplasia (Min) mutation, a heterozygous nonsense mutation at codon 850 of the
Apc gene [24,41]. After somatic mutation of the second Apc allele, Min mice develop
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multiple polyps or adenomas in the small intestine as well as a small number of colonic
adenomas at around 2–3 months of age [41]. This animal model is the most widely used
genetically engineered mouse model for cancer studies that involve the gastrointestinal tract
[42,43]. Among the organs examined in this study, there was only one malignant tumor
(adenocarcinoma) found in the small intestine of a control animal. The nuclei were enlarged
and pleomorphic with variable loss of their polarity. The glandular structure was distorted
and resembled that seen in overt colonic carcinoma. The highest tissue damage was
observed in the colon of control group animals under the same conditions as applied to the
other tissues. We hypothesize that this reflects the fact that the colonic wall, including the
mucosa and the submucosa, is much thinner than that of the other organs.
Most of the adenomas found were sessile and broad-based and were composed of papillary
projections of lamina propria covered by an epithelium. There were significantly less
adenomas found in the ceca. The greatest loss in mucin secretion was displayed in severely
dysplastic glands of control group animals sacrificed at the 17th week of the experiment.
The glands were closely packed and a structural atypia, e.g. "back to back" arrangement was
more prominent. Nuclei were plump but still uniform and smaller than those in
carcinomatous glands. Cytological abnormalities detected included cellular and nuclear
pleiomorphism and loss of polarity. Architectural abnormalities included the presence of
intraglandular papillary projections and of cribriform and solid epithelial areas. There were,
however, no major differences in animal tissues collected from animals sacrificed at
different time periods due to premature excess loss of body weight. The tumors found in the
treatment group showed some features of papillary carcinoma-grooved nuclei and papillary
architecture, but these were not consistent. Future work could incorporate additional cellular
markers to reveal immunocytochemical indices of tumor growth dynamics such as
proliferation-associated antigens (e.g. CCL2, PCNA) and to examine reciprocal correlations
between the intensity of apoptosis and the expression of such pro- and anti-apoptotic cell
markers as caspase-3 (cas-3) and Ki-67 antigen.
Many cancers are associated with a chronic inflammatory process [44–46]. Inflammatory
bowel disease, including both ulcerative colitis and Crohn’s disease, has a well-established
association with the development of colorectal cancer [47]. In contrast to colorectal cancers
with a well-defined genetic basis like familial adenomatous polyposis, it appears that
chronic inflammation predisposes to the development of colorectal cancers in the setting of
inflammatory bowel disease [48]. This is supported by the fact that for example anti-
inflammatory agents decrease the risk of developing colorectal cancer in inflammatory GI
diseases. The chronic inflammatory response represents a fine balance between active
inflammation, repair, and degradation that occurs in response to a persistent biochemical
stimulus over a prolonged period of time. Activation of leukocytes in response to such an
ongoing stimulus leads to the production of chemokines, cytokines, and reactive oxygen
species, resulting in accumulated tissue destruction and subsequent attempts at healing via
remodeling, angiogenesis, and connective tissue replacement [48]. Our results confirm the
previously reported studies which found increased IL-6 immunoreactivity in cancerous
lesions when compared to normal colon mucosa and that IL-6 concentrations correlated with
tumor tissue concentrations and proliferative activity [31,34,49]. The differences in
inflammation levels among the treatment groups could be the result of stimulation of
mucosal barrier function, decreased binding to or penetration of pathogens to mucosal
surfaces, or altering immunoregulation (decreasing proinflammatory and promoting
protective molecules). Another marker for reduced inflammation levels in the treatment
group is IL-12. IL-12 is a chemokine expressed by various leukocytes and lymphocytes like
dendritic cells, macrophages and B cells in response to stimulation by various antigens.
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Lactoferrin, a multifunctional protein that is part of the innate defense against infection and
inflammation is present in milk, saliva and other exocrine secretions as well as in neutrophil
granules. It has a number of biological functions, including antimicrobial and
immunomodulatory effects in vitro and in vivo [50]. Its levels are elevated in fecal samples
in inflammatory bowel disease patients [51,52]. During intestinal inflammation, leukocytes
infiltrate the mucosa, which results in increased lactoferrin in the feces [52,53]. We
observed a decrease in concentration levels throughout the experiment in the treatment
group, with significant difference in the last week (Fig. 3a). In addition, we quantified the
levels of C-reactive protein, a well-known acute-phase marker of inflammation in the body
and it has been reported to be an independent prognostic factor of colorectal cancer [54,55].
Although CRP is considered non-specific systemic marker of inflammation, many
researchers have hypothesized that CRP may act as a biomarker for chronic low-grade
intestinal inflammation and the subsequent development of colorectal cancer [56]. In this
animal model, the development of intestinal tumors occurs early in life, therefore, there is a
presence of constant chronic inflammation. Although the levels of CRP in the fecal samples
were not significantly different at the last week of the experiment, there was an observed
trend between control and treatment group, with higher levels determined in control group.
Growing evidence suggests that apoptosis is relevant in some infectious diseases by
regulating immune responses [57]. As expected, we observed a high occurrence of cell
turnover in the tumors found in aniamls treated with oxaliplatin. We detected only scarce
amount of apoptotic cells on the surface of the tumor from control group animal, proving
that the process of apoptosis is suppressed in inflamed tissue which allows cells with
precancerous genetic mutations to live and grow into a cancer instead of having a normal,
programmed cell death. Reduced mucin production in the intestine accompanies both
inflammatory bowel disease and colon cancer and has been postulated as allowing irritation
of the underlying epithelial cells by the intestinal microbiota [47]. We investigated the
mucin production, a consequence of inflammatory state of the intestinal tissue by staining
with alcian blue to detect mucous-producing Goblet cells. As predicted, an increased cell
staining was observed in healthy, well-defined microvilli of the intestine, much decreased
cells count within and around tumor areas. There is a strong evidence that NO itself, through
its proinflammatory effects, may play an important role in carcinogenesis [48]. The
increased production of nitric oxide could be a consequence of an increased level of
oxidative stress, a consequence of the proinflammatory environment in the intestines of the
mice.
We assessed the inflammatory changes in the small and large intestines’ animals from
control and treatment group by immunohistochemistry using cyclooxygenase-2 (Cox-2),
cleaved caspase-3, Ki-67 and mdm-2 antibodies. Expression of Cox-2 is believed to play an
important role in adenoma formation in murine polyposis models and is critical for the
development of colorectal neoplasia [58]. Cox-2 expressing cells were mostly found in the
tumors of control group animals, distributed throughout the entire tumors. COX-2
expression has a large impact on adenoma growth in ApcMin mice, where treatment with a
COX-2-specific inhibitor is known to markedly reduce both the numbers and growth of
adenomas. Furthermore, marked upregulation of COX-2 occurs in various cells including
endothelial cells during stress and in inflammatory conditions such as sepsis. Caspase-3 is
an enzyme crucial to the apoptotic process. Detection of activated caspase-3 is a valuable
tool to identify dying cells even before morphological features of apoptosis are present [59].
Cleaved caspase-3 expressing cells were primarily expressed in apoptotic cells, apoptotic
bodies and in some tumor cells of treatment group animals, mostly at the base and surface.
They were localized to the nucleus and to the cytoplasm diffusely, thus they were fewer in
the normal mucosa. In comparison with TUNEL method, cleaved caspase-3 staining was
able to identify more apoptotic cells, most likely even pre-apoptotic cells. The Ki-67 nuclear
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antigen is present throughout most of the cell cycle, and Ki-67 immunohistochemistry
provides a reliable means of rapidly evaluating the growth fraction of normal and neoplastic
cell populations [60]. Ki-67, a marker of proliferating cells, was highly expressed in
adenomas of the control and treatment group, in both small and large intestine. We did not
observed significant correlation in detection of apoptotic cells stained with cleaved
caspase-3 and Ki-67. Mdm-2 gene amplification and overexpression occur in several types
of tumors and are often associated with poor prognosis. Furthermore inhibition of mdm-2
expression enhances the activation of p53 by a DNA-damaging cancer chemotherapy agent
in a synergistic fashion [49]. From immnuhistochemistry staining we detected increased
levels of mdm-2 expressing cells in the control animal intestinal tissue as opposed to the
treated condition.
5. Conclusions
In the present study, we designed a novel “particle in a particle” formulation where
oxaliplatin was first loaded into nanoparticles composed of lipid like polymeric molecules
which were later encapsulated in micro-sized alginate based particles. We believe that this
combinatorial approach allowed for an improved and targeted delivery of the drug to the
lower gastrointestinal tract where the tumor cells reside. This was confirmed after orally
delivering formulation to the animals for 17 weeks which yielded in significant
improvement in both tumor progression and morbidity when compared to control group. In
summary, these findings confirm the previously reported potential of oxaliplatin in
suppression and delaying of intestinal tumorigenesis. To our knowledge these are the first
data to indicate that oral delivery of oxaliplatin induces reduction of protein concentration of
proinflammatory cytokines, tumor burden, and morbidity when delivered orally. We believe
this approach may have utility for the delivery of therapeutics to a variety of diseases in
lower GI tract.
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Fig. 1.
Animal body weights over 17-week trial; control group – animals gavaged with empty
alginate-chitosan (AC) microcapsules suspended in PBS, treatment group – animals gavaged
with AC microencapsulated lipidoid and oxaliplatin nanoparticles suspended in PBS (A);
Animal survival profile (B).
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Fig. 2.
The effect of treatments on IL-12 concentrations in serum (A) and IL-6 concentrations in
serum (B) in animals, Control group – animals gavaged with empty alginatechitosan (AC)
microcapsules suspended in PBS, Treatment group – animals gavaged with AC
microencapsulated lipidoid and oxaliplatin nanoparticles suspended in PBS. Data represent
the mean ± SD of concentration levels per group. Asterisks: statistical differences (p < .05)
when compared to control.
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Fig. 3.
The effect of treatments on lactoferrin concentrations (3A) and C-reactive protein (3B) in
fecal samples of animals, Control group – animals gavaged with empty alginatechitosan
(AC) microcapsules suspended in PBS, Treatment group – animals gavaged with AC
microencapsulated lipidoid and oxaliplatin nanoparticles suspended in PBS. Data represent
the mean ± SD of concentration levels per group. Asterisks: statistical differences (p < .05)
when compared to control.
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Fig. 4.
H&E tissue staining of mice polyps in small intestine, colon and cecum for control and
oxaliplatin treatment group. Control mice had a higher number of polyps, indicated with red
arrows, in the small intestine, colon and cecum compared with oxaliplatin treatment group.
(For interpretation of the references to colour in this figure legend, the reader is referred to
the web version of this article.)
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Fig. 5.
Terminal deoxynucleotidyl transferase-Mediated dUTP nick end labeling, representative
tumor from control group animal (A) and oxaliplatin treatment (B); alcian blue staining of
Goblet cells shows reduced mucin production within adenoma (C) compared to normal
intestinal tissue expressing mucin producing cells (D); evidence of increased nitrosative
stress in control group animals showing intestinal microvilli (E) relative to microvilli
obtained from treatment group animal (F); magnification 4×.
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Fig. 6.
Immunohistochemical analysis of adenomas found in the small intestine (A) and colon (B)
stained for Cox-2, Cleaved Caspase-3, Ki-67 and Mdm-2. Each panel compares adenomas
found in the control and treatment group. Section magnified is selected in a red rectangle
and stained cells are pointed out with red arrows. All shown sections are at 4× magnification
(bar = 1000um) and further magnified to show details at 20× (bar = 100 um).
Immunohistochemistry was performed using Cox-2 (Santa Cruz, CA), Cleaved Caspase-3
(Cell Signaling), Ki-67 (Dako) and Mdm-2 (Santa Cruz, CA) antibodies at a 1:500 dilution.
Immunohistochemical signal was detected by secondary biotinylated goat anti-mouse
antibody (1:500 dilution; Santa Cruz, CA) followed by Vector ABC tertiary kit (Vector
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Laboratories, Burlingame, CA, USA) according to the manufacturer’s instructions. All
immunohistochemistry was performed on a BondMax machine (Vision Biosystems,
Newcastle, UK) according to the manufacturer’s instructions and involved antigen retrieval
by BondMax Epitope retrieval solution heated on the machine for 20 min. (For
interpretation of the references to colour in this figure legend, the reader is referred to the
web version of this article.)
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